Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Innate Pharma S.A. furnished a Form 6-K as a foreign private issuer, providing its H1 2025 Half-Year Financial Report for the period from January 1 to June 30, 2025. The half-year report is attached as Exhibit 99.2 and contains the company’s detailed financial and operating information.
The company states that this Form 6-K and Exhibit 99.2 (excluding the statutory auditors' review report on page 49) are incorporated by reference into its existing registration statements on Form F-3 and Form S-8, meaning the half-year information becomes part of those U.S. securities offering documents.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
FAQ
How many Innate Pharma SA (IPHYF) SEC filings are available on StockTitan?
StockTitan tracks 33 SEC filings for Innate Pharma SA (IPHYF), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.
When was the most recent SEC filing for Innate Pharma SA (IPHYF)?
The most recent SEC filing for Innate Pharma SA (IPHYF) was filed on September 17, 2025.